Albuterol pregnancy
Pro Research Analysisby 
Searched over 200M research papers for "albuterol pregnancy"
Albuterol Use During Pregnancy: A Comprehensive Overview
Introduction to Albuterol and Pregnancy
Albuterol, a commonly used beta-agonist bronchodilator, is frequently prescribed to manage asthma symptoms. Its use during pregnancy raises questions about its safety for both the mother and the fetus. This article synthesizes current research findings on the effects and safety of albuterol use during pregnancy.
Short-term Effects on Maternal and Fetal Circulations
Research has investigated the short-term circulatory effects of inhaled albuterol on pregnant women and their fetuses. A study involving 12 asthmatic patients between 33 and 39 weeks' gestation found that the maximum recommended dose of inhaled albuterol did not affect maternal blood pressures, heart rates, or the systolic/diastolic ratios of the uterine arcuate and umbilical arteries. Additionally, fetal heart rates and aortic velocities remained stable during the first two hours after dosing. These findings suggest that short-term use of albuterol at recommended doses does not pose immediate circulatory risks to either the mother or the fetus.
Maternal Reporting vs. Medical Records
The accuracy of maternal reporting of medication use during pregnancy, including albuterol, has been compared to medical records. A study involving pregnant women with asthma found that albuterol was the most frequently reported medication (77.9%). However, the agreement between maternal reports and medical records for albuterol use was relatively low, with a kappa coefficient of 0.21 and 64.5% agreement. This discrepancy indicates that maternal self-reporting may capture more instances of albuterol use than medical records, highlighting the importance of considering both sources when studying medication impacts during pregnancy.
Conclusion
Current research indicates that short-term use of inhaled albuterol at recommended doses does not adversely affect maternal or fetal circulations. However, discrepancies between maternal reports and medical records suggest that self-reporting may provide a more comprehensive account of albuterol use during pregnancy. These findings underscore the need for careful monitoring and documentation of medication use to ensure the safety and well-being of both mother and child.
Sources and full results
Most relevant research papers on this topic